Status:
UNKNOWN
Leflunomide Associated With Topical Corticosteroids for Bullous Pemphigoid
Lead Sponsor:
University Hospital, Limoges
Conditions:
Bullous Pemphigoid
Eligibility:
All Genders
65+ years
Phase:
PHASE2
Brief Summary
Bullous pemphigoid (BP) is the most common blistering auto-immune disease of skin with an incidence estimated to 400 new cases per year. Topical corticosteroid therapy is considered the standard treat...
Detailed Description
Pre-inclusion stage: Case history, clinical examination, laboratory study, inclusion criteria checking. Inclusion stage: Inclusion and exclusion criteria checking, clinical examination, disease follo...
Eligibility Criteria
Inclusion
- Adult ≥ 65 years old
- Bullous pemphigoid :
- Newly diagnosed bullous pemphigoid : No treatment or topical corticosteroids therapy for less than one month
- BP diagnosed : Resistance of the BP to the treatment or recurrence 6 months at least after diagnosis
- Follow up monthly during one year accepted
- Written Inform Consent
Exclusion
- None
Key Trial Info
Start Date :
September 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
54 Patients enrolled
Trial Details
Trial ID
NCT00802243
Start Date
September 1 2007
Last Update
December 4 2008
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Limoges University Hospital
Limoges, France, 87042
2
Bordeaux University Hospital
Pessac, France, 33604
3
Toulouse University Hospital
Toulouse, France, 31059